Development of Neutropenic Murine Models of Iron Overload and Depletion to Study the Efficacy of Siderophore-Antibiotic Conjugates.
Siderophore-antibiotic conjugates have increased in vitro activity in low iron environments where bacteria express siderophores and associated transporters. The host immune hypoferremic response reduces iron availability to bacteria, however, patients with iron overload or deficiency may have altered ability to restrict iron which may affect the efficacy of siderophore-antibiotic conjugates. In vivo models of infection with iron overload and deficiency are needed to perform this assessment.The standard neutropenic murine thigh infection model was supplemented with iron altering treatments: iron dextran 100 mg/kg daily for 14 d to load iron, or deferoxamine 100 mg/kg daily plus a low-iron diet for up to 30 days to deplete iron. Human-simulated regimens of cefiderocol and meropenem were administered in both models to assess any impact of iron alteration on plasma pharmacokinetics.Median iron in overloaded mice was significantly higher than controls in plasma (1657 v. 336 μg/dL, p<0.001), liver (2133 v. 11 μg/g, p<0.001), and spleen (473 v. 144 μg/g, p<0.001). At 30 d, depleted mice had significantly lower iron than controls in liver (2.4 v. 6.5 μg/g, p<0.001) and spleen (72 v. 133 μg/g, p=0.029), but not plasma (351 v. 324 μg/dL, p=0.95). Cefiderocol and meropenem plasma concentrations were similar in iron overloaded and control mice, but varied in iron depleted mice.The iron overloaded murine thigh infection model was established and human-simulated regimens of cefiderocol and meropenem were validated therein. While deferoxamine successfully reduced liver and splenic iron, this depleting treatment altered the pharmacokinetics of both antimicrobials.